MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Immunohistochemistry or IHC

Often used to diagnose cancer, Immunohistochemistry or IHC is a process by which antibodies are detected in tissue samples by use of a specific antigen or antigens. IHC is also widely used in basic research to understand the distribution and localization of biomarkers in different parts of a tissue (also see “Serum Marker/Blood Test“).

Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis

Oncotarget 2017 August [Link] Wang LM, Shi ZW, Wang JL, Lv Z, Du FB, Yang QB, Wang Y Abstract BACKGROUND: Conventional measurements are not always helpful in the diagnosis of malignant mesothelioma (MM). Increasing studies indicate that loss of BRCA1-associated protein 1 (BAP1) detected by immunohistochemistry (IHC) is a useful diagnostic marker for MM. In […]

Comments Off on Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis

Role of proton-coupled folate transporter in pemetrexed-resistance of mesothelioma: clinical evidence and new pharmacological tools.

Annals of Oncology 2017 September [Epub ahead of print] [Link] Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, Thunnissen E, Hou Z, Muller IB, Struijs EA, Perrino M, Jansen G, Matherly LH, Peters GJ Abstract BACKGROUND: Thymidylate synthase (TS) has a predictive role in pemetrexed-treatment of mesothelioma, however additional chemoresistance mechanisms […]

Comments Off on Role of proton-coupled folate transporter in pemetrexed-resistance of mesothelioma: clinical evidence and new pharmacological tools.

Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma

JAMA Oncology 2017 September [Epub ahead of print] [Link] Hung YP, Dong F, Watkins JC, Nardi V, Bueno R, Dal Cin P, Godleski JJ, Crum CP, Chirieac LR Abstract IMPORTANCE: Malignant peritoneal mesothelioma is a rare, aggressive tumor arising from the peritoneal lining, induced by asbestos, therapeutic radiation, or germline mutations. Nevertheless, the molecular features […]

Comments Off on Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

The Lancet. Oncology 2017 September [Epub ahead of print] [Link] van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G Abstract BACKGROUND: TargomiRs are minicells (EnGeneIC Dream Vectors) loaded with […]

Comments Off on Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma

Modern Pathology 2017 September [Epub ahead of print] [Link] Vivero M, Bueno R, Chirieac LR Abstract Pleural diffuse malignant mesothelioma typically presents during the seventh decade of life and has poor prognosis. Recent epidemiologic studies have shown differences between young and older mesothelioma patients, but the biology of pleural mesothelioma in young patients is poorly […]

Comments Off on Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma

The epithelioid, BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma

Histopathology 2017 September [Epub ahead of print] [Link] Chou A1, Toon CW1, Clarkson A1, Sheen A, Sioson L1 Gill AJ Abstract AIMS: Mesothelioma is a relatively uncommon but highly malignant neoplasm. Most patients die of disease within one year of diagnosis, but some have prolonged survival. Prospective identification of these longer-term survivors may help guide […]

Comments Off on The epithelioid, BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma

Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma

Human Pathology 2017 August 12 [Epub ahead of print] [Link] Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M Abstract Diffuse malignant mesothelioma of the pleura is a highly aggressive tumor typically associated with short survival. […]

Comments Off on Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma

Evaluating the effect of immune cells on the outcome of patients with mesothelioma

British Journal of Cancer 2017 August 17 [Epub ahead of print] [Link] Chee SJ, Lopez M, Mellows T3, Gankande S, Moutasim KA, Harris S, Clarke J, Vijayanand P, Thomas GJ1, Ottensmeier CH Abstract BACKGROUND: We systematically assessed the prognostic and predictive value of infiltrating adaptive and innate immune cells in a large cohort of patients […]

Comments Off on Evaluating the effect of immune cells on the outcome of patients with mesothelioma

The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: Evidence-Based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.

Human Pathology 2017 August 4 [Epub ahead of print] [Link] Marchevsky AM, et. al. Abstract Immunohistochemistry is used to distinguish sarcomatoid malignant mesotheliomas (SMM) from spindle cell and pleomorphic carcinomas (SPC) but there are no guidelines on how to interpret cases that show overlapping or equivocal immunohistochemical findings. A systematic literature review of the immunophenotype […]

Comments Off on The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: Evidence-Based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.

Magnetic nanoparticles-based therapy for malignant mesothelioma

Romanian Journal of Morphology and Embryology [2017] [Link] Mîndrilă I, Buteică SA, Mihaiescu DE, Burada F, Mîndrilă B, Predoi MC, Pirici I, Fudulu A, Croitoru O Abstract This work was aimed to analyze the versatility of the chick embryo chorioallantoic membrane (CAM) as in vivo model for the study of the malignant pleural mesothelioma (MPM) […]

Comments Off on Magnetic nanoparticles-based therapy for malignant mesothelioma